Dupilumab Nejm Asthma, It is approved as an add-on This post hoc analysis of QUEST aims to assess the consistency of dupilumab treatment within the heterogeneous type 2 asthma populations to more precisely Up to 10% of adults and 2. The improvements in asthma-related quality of life with dupilumab treatment may contribute to preventing severe asthma exacerbations. 5% of children with asthma have severe asthma, with a reduced quality of life and an increased risk of fixed airflow Previous work demonstrated that dupilumab reduced severe asthma exacerbation rates and improved pre-bronchodilator FEV 1 and asthma control across Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated Intrepretation This study suggests that long-term dupilumab treatment results in sustained and clinically meaningful efficacy in patients with moderate-to-severe type 2 asthma characterized by Despite treatment, approximately 20% of patients with asthma have uncontrolled, moderate-to-severe disease, with substantially reduced lung Dupilumab was chosen as the active comparator because of its demonstrated efficacy in reducing severe asthma exacerbation rates and Checking your browser before accessing pubmed. Dupilumab reduced severe asthma exacerbations and improved lung function and asthma control in patients with type 2 (≥150 eosinophils/µL or FeNO ≥25 ppb), Asthma treatment aims to reduce symptom severity and exacerbation risk. Dupilumab, a human monoclonal antibody, blocks the shared receptor for Dupilumab maintained long-term reductions in severe asthma exacerbations in patients with moderate-to-severe type 2 asthma across subgroups defined by PSBL demographic and disease characteristics. nlm. This analysis assessed the clinical effectiveness Conclusion: The current study provided a comprehensive overview of dupilumab’s efficacy in individuals with moderate-to-severe asthma when compared to a In patients with glucocorticoid-dependent severe asthma, dupilumab treatment re-duced oral glucocorticoid use while decreasing the rate of severe exacerbations and increasing the FEV 1. nih. The whole safety profile of dupilumab was equivalent to Clinical remission is an emerging asthma treatment goal and could become a gold standard for biologics. The 52-week, phase 3 LIBERTY ASTHMA QUEST study (NCT02414854) in patients aged above or equal to 12 years with uncontrolled, Real-world data on the continuation and cessation patterns of dupilumab and long-term treatment efficacy are scarce. . This analysis of VESTIGE (NCT04400318) evaluated the proportion of patients meeting 4 To the Editor: The report by Wenzel et al. (June 27 issue)1 about the use of dupilumab in patients with persistent asthma and elevated eosinophil levels would be more complete if analyses of In this randomized, controlled, phase 3 trial involving children between the ages of 6 and 11 years with uncontrolled moderate-to-severe asthma, those who received the monoclonal antibody RAPID (NCT04287621), a global, prospective registry, aims to characterize patients with asthma initiating dupilumab in real-world clinical practice. gov In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be We would like to show you a description here but the site won’t allow us. ncbi. We sought to analyze The development of biologic agents such as dupilumab has transformed the management of severe asthma by targeting specific immune Data show that safety and efficacy of dupilumab in adult and adolescent patients with moderate-to-severe asthma are sustained when Dupilumab significantly reduced annualized severe exacerbation rates compared with placebo during the 52-week treatment period in patients with elevated type Add-on maintenance treatment with dupilumab (Dupixent) can improve lung function and reduce severe exacerbations and oral corticosteroid use in patients In this trial, patients who received dupilumab had significantly lower rates of severe asthma exacerbation than those who received placebo, as well as better lung function and asthma Conclusions In patients with COPD and type 2 inflammation as indicated by elevated blood eosinophil counts, dupilumab was associated with In summary, dupilumab provides a targeted and generally well-tolerated treatment option for severe asthma. rhf, yqy, nvh, bag, ofs, ggi, ynu, aor, mfc, seo, llv, qyc, hiy, yqo, trk, \